1-5 of 5
Anna Marie Juanitez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6602–6603.
https://doi.org/10.1182/blood-2022-167950
Published: 2022
Journal Articles

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Rafic J. Farah, Seung Tae Lee, Amynah Pradhan, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2022) 140 (Supplement 1): 2289–2291.
https://doi.org/10.1182/blood-2022-167887
Published: 2022
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Anna Marie Juanitez, Amynah Pradhan, Amy Hillsman, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3537.
https://doi.org/10.1182/blood-2021-147032
Published: 2021
Journal Articles

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Craig J. Thomas, PhD, Michele Ceribelli, PhD, Frances Anne Tosto, MS, Craig A. Portell, MD, Rafic J. Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141447
Published: 2020
Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2867.
https://doi.org/10.1182/blood-2019-125990
Published: 2019